Hatteras Venture Partners
Venture capitalResearch Triangle · Seed–Series C · 28 people tracked
Also known as HATTERAS VENTURE ADVISORS III, LLC · HATTERAS VENTURE ADVISORS IV, LLC · HATTERAS VENTURE ADVISORS V LLC · HATTERAS VENTURE ADVISORS VI, LLC · HATTERAS VENTURE ADVISORS VII, LLC
Investment thesis
Hatteras Venture Partners invests in high-quality science and teams pursuing breakthrough ideas with significant potential impact for patients. The firm prioritizes therapeutic and diagnostic advances as well as companies disrupting the healthcare status quo. Beyond providing capital, it supports portfolio companies with team recruitment, portfolio strategy, business development, and regulatory and clinical planning, aiming to build transformational companies that reach value inflection quickly and efficiently. Based in North Carolina's Research Triangle, the firm is a leader in the Southeast while maintaining a broad North American investment footprint, drawing on over 25 years of experience across more than 100 companies.
Source: firm website, verified Aug 3, 2026.
Team · 28 people
from the firm's website & public directories
What they invest in
from 60 of 135 portfolio companiesBiotech ×38Healthtech ×33Medical Devices ×24Digital Health ×10AI & Machine Learning ×9Deep Tech ×8AgTech ×2Hardware ×2
HQs:United States×58United Kingdom×1
Investments · 135 tracked
founders shown can be your intro pathCVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
BiotechHealthtechMedical DevicesAustin, US
Craig Palmer(Executive Officer)Geoff Pardo(Director)Nadim Yared(Executive Officer, Director)Dean Bruhn-Ding(Executive Officer)John Brintnall(Executive Officer)Liz Galle(Executive Officer)
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
BiotechAustin, US
Walter Loewenbaum(Director)Josiah Hornblower(President/CEO)
Avivomed is a medical device company developing minimally invasive neuromodulation therapies for patients with obstructive sleep apnea.
BiotechDeep TechHealthtechMedical DevicesRoseville, US
Paul Mazanec(Chief Executive Officer)Theresa C. Pappas(Director)Ketan Patel(Director)Casper de Clercq(Director)Douglas Reed(Director)Stephen Masson(Executive Officer, Director)
Contego Medical develops cardiovascular intervention technologies, founded by an interventional cardiologist inventor.
HealthtechMedical DevicesRaleigh, US
Ravish Sachar(CEO & Founder)Paul Sanders(Chief Operating Officer)Elizabeth K. Saylors(Corporate Secretary)
iRiva Medical is a development-stage medical device company building neuromodulation technology platforms to treat patients with chronic diseases.
BiotechHealthtechMedical DevicesMinneapolis, US
Steve Masson(President & CEO)Mudit K. Jain(Co-Founder and Chairman of the Board)Lynn Elliott(Co-Founder and Director)
Trefoil Therapeutics develops ophthalmologic drugs, with a team focused on drug development and commercialization in the eye-care field.
BiotechHealthtechSan Diego, US
Ralph Bradshaw(Director)Christy Shaffer(Director)Schalon Newton(Executive Officer)David Eveleth(Executive Officer, Director)
BEKhealth provides AI-powered clinical intelligence software that extracts data from electronic health records to enable faster clinical trial recruitment and real-world evidence generation.
AI & Machine LearningDigital HealthHealthtechBranford, US
Joshua Ransom(Executive Officer)David Levin(Executive Officer, Director)inJason Baumgartner(Executive Officer, Director)
BoardBobby Bahram(Director)Jeanne Hecht(Director)
Board seatJohn Crumpler· per SEC Form D
BiotechAlpharetta, US
William Humphries(Director)Gerald Cagle, Ph.D.(Director)Evgeny Zaytsev(Director)Derek Yoon(Director)Christy L. Shaffer, Ph.D.(Director)Charles Deignan(Executive Officer)
Board seatClay ThorpChristy Shaffer· per SEC Form D
BiotechBrisbane, US
John S. Patton, Ph.D(Executive Officer, Director)Adam Stern(Director)Tyler Martin, M.D.(Executive Officer, Director)Greg Zante(Executive Officer)Augustine P.Y. Chow, M.D.(Director)Lisa E. Porter, M.D.(Executive Officer)
Board seatKenneth B. Lee, Jr.· per SEC Form D · $15M raise · filed Jun 2020
HealthtechAustin, US
Thomas Schnettler(Director)Christian Lange(Director)Jacylyn Bodmer(Chief Information Officer)Karen Flaherty(Vice President, Finance)Amy Staedtler(Chief Legal Officer)Scott Treiber(Chief Operating Officer)
Board seatJohn Crumpler· per SEC Form D
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
BiotechResearch Triangle Park, US
Timothy Sullivan(Director)Peter Kolchinsky(Director)Mark A. Velleca(Executive Officer, Director)Glenn Muir(Director)Gregory Mossinghoff(Executive Officer)Seth Rudnick(Director)
Board seatClay ThorpChristy Shaffer· per SEC Form D
BiotechDurham, US
CLAY THORP(Director)MICHAEL MILBURN(Executive Officer, Director)ARNOLD LEVINE(Director)CHARLES PEROU(Director)Prasanth Reddy(Director)Don Hardison(Director)
Board seatMyla Lai-GoldmanClay Thorp· per SEC Form D
Franklin, US
Justin Neece(Executive Officer, Director)Fred Goldwater(Director)Martin Seeger(Executive Officer)Mark Tomaino(Director)
Board seatFred Goldwater· per SEC Form D · $5M raise · filed Dec 2018
Ilumivu provides software for early detection and management of conditions such as hypertension, a-fib, diabetes, and sleep apnea, using machine learning algorithms that process data from standard smartwatches via the Cardiogram app.
AI & Machine LearningDigital HealthHealthtechFairview, US
Sandeep Goel(Executive Officer, Director, Promoter)
Board seatLauren Pierce Flickinger· per SEC Form D
BiotechRtp, US
Matthew Cohen(Director)Anil Goyal(Executive Officer, Director)Lev Osherovich(Director)Jenny Ting(Director)Benjamin Scruggs(Director)Mark Vellaca(Director)
Board seatMark Velleca· per SEC Form D · $4M raise · filed Jan 2023
Portland, US
Board seatLauren Pierce Flickinger· per SEC Form D · $5.1M raise · filed Dec 2025
Cary, US
Board seatJohn Crumpler· per SEC Form D · $1.5M raise · filed Jun 2018
HealthtechNew York, US
Mitzie Garland(Executive Officer)Kate Hershov(Director)Fredric Eshelman(Director)Jonathan Comerford(Director)
Board seatJohn Crumpler· per SEC Form D · $2.3M raise · filed Aug 2020
BiotechBoston, US
Clay Thorp(Director)Kate Blanchard(Executive Officer, Director, Promoter)Doug Jamison(Director)Jonathan Meltzer(Director)Robin Y. Smith(Executive Officer, Director, Promoter)
Board seatClay Thorp· per SEC Form D · $28.7M raise · filed Sep 2020
PhaseBio is a company focused on developing treatments for cardiovascular disease, which is a leading cause of death in the United States.
BiotechHealthtechMedical DevicesMalvern, US
Joel Sussman(Executive Officer)James Barrett(Director)Michael Gutch(Director)Justin Klein(Director)Jonathan Mow(Executive Officer, Director)Asish K. Xavier(Director)
Board seatRobert IngramClay Thorp· per SEC Form D
BiotechDurham, US
Clay Thorp(Director)Heather Madsen(Ms. Madsen is a director and the CEO of the issuer.)William Wiesler(Executive Officer, Director)
Board seatHolden ThorpClay ThorpChristy Shaffer· per SEC Form D · $2.5M raise · filed Nov 2025
Durham, US
Steven D. Weinstein(Director)Robert J. Schotzinger, M.D., Ph.D.(Executive Officer, Director)Robert Ingram(Director)Kristopher A. Wood(Director)Adrian Howd(Director)Andrew von Eschenbach(Director)
Board seatRobert Ingram· per SEC Form D
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Bruce Booth(Director)Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)Mary Thistle(Director)Stefan Vitorovic(Director)Evan Thackaberry(Executive Officer)
Board seatClay Thorp· per SEC Form D
Wildflower provides digital engagement, health coaching, and value-based care services for women's health, connecting patients, providers, and payers across the healthcare system.
Digital HealthFemTechHealthtechSan Francisco, US
Leah Sparks(President/CEO of Issuer)Kim Russell(Chief Financial Officer of Issuer)
BoardDan Galles(Director of Issuer)Ezra Mehlman(Director of Issuer)Ralph Sabin(Director of Issuer)
Board seatJohn Crumpler· per SEC Form D
410 Medical makes LifeFlow, a hand-operated rapid infuser that lets clinicians quickly deliver blood or fluids to critically ill patients needing volume resuscitation.
HardwareHealthtechMedical DevicesDurham, US
KYLE CHENET(Executive Officer, Director)BOBBY HELMEDAG(Director)JEFF TERRELL(Director)Mark Donald Piehl(Executive Officer, Director)STANLEY D. LYNALL(Director)DANIEL S. DUFFY(Director)
BiotechRaleigh, US
John Fahy(Director)THOMAS MATHERS(Executive Officer, Director)James Shaffer(Executive Officer, Director)
BoardChristy Shaffer(Director)Rishi Gupta(Director)Tim Shannon(Director)
Altis Biosystems builds RepliGut®, human intestinal tissue models grown from human intestinal stem cells that provide human-relevant preclinical data for drug absorption, metabolism, toxicity, and disease modeling.
BiotechDeep TechHealthtechMedical Devices
Christopher Sims(Executive Officer)Jimmy Smedley(Executive Officer)Samuel Franklin(Director)Joseph McMahon(Director)Michael Biron(Executive Officer, Director)Swetha Peddibhotla(Senior Scientist)
Axonis Therapeutics develops medicines targeting KCC2 to restore inhibition in the brain, with a focus on treating neurological disorders including epilepsy and pain.
BiotechMedical DevicesBoston, US
Shane Hegarty(Executive Officer)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Executive Officer, Director)
BoardCorey . Goodman(Director)Jonathan Leff(Director)Raymond J. Kelleher(Director)
Durham, US
Kevin Schulman(Director)Seth W. Glickman(Executive Officer, Director)David Levin(Executive Officer, Director)Donald A. Holzworth(Director)Edward Berlin(Director)
Boston Immune Technologies & Therapeutics is a biotechnology company developing TNFR (tumor necrosis factor receptor) superfamily antagonists as therapeutics.
BiotechHealthtechBoston, US
Cardiosense develops the CardioTag, a noninvasive point-of-care cardiac monitoring device that measures pulmonary capillary wedge pressure to enable early detection and management of worsening heart failure across emergency, inpatient, and outpatient settings.
AI & Machine LearningDigital HealthMedical DevicesChicago, US
Jeff Terrell(Director)Omer Tolga Inan(Director)Amit K. Gupta(Executive Officer, Director)Andrew Michael Carek(Executive Officer)Daniel Gottlieb(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Fund performance · per public LP disclosures · 2
as of Sep 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Hatteras Venture Partners VLPs: San Diego City Employees' Retirement System | 2015 | — | 35.3% | 2.08x | 1.35x |
| Hatteras Venture Partners III, L.P.LPs: North Carolina Retirement Systems | 2007 | — | 0.3% | — | — |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Feb 2023
Disclosed stake · filed Jan 2023
Disclosed stake · filed Dec 2019
Disclosed stake · filed Jul 2019
Disclosed stake · filed Jul 2019
Disclosed stake · filed Nov 2018
Disclosed stake · filed Nov 2018
Disclosed stake · filed Mar 2018
Disclosed stake · filed Apr 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Jun 2016
5 insider ownership filings (Forms 3/4/5)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- What stage does Hatteras Venture Partners invest at?
- Hatteras Venture Partners invests at the Seed, Series A, Series B, Series C stages.
- What is Hatteras Venture Partners's typical check size?
- Hatteras Venture Partners typically writes checks of $500K – $4M.
- What sectors does Hatteras Venture Partners focus on?
- Hatteras Venture Partners focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
- Where is Hatteras Venture Partners located?
- Hatteras Venture Partners is headquartered in Research Triangle, US.
- Does Hatteras Venture Partners lead rounds?
- Hatteras Venture Partners typically participates in rounds rather than leading them.
Images
Co-investors · 23
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Arboretum Ventures is a Midwest-based healthcare venture capital firm that invests in early-stage healthcare startups across medical devices, life science tools and diagnostics, tech-enabled care delivery, and pharma adjacencies.
Broadview Ventures is an impact investor focused on accelerating the development of technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
OUP (Osage University Partners) is a venture capital firm that backs science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Vensana Capital is a venture capital and growth equity investment firm focused on partnering with entrepreneurs building breakthrough medical technology innovations to transform healthcare.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
Fusion Fund is an early-stage venture capital firm backing startups with technical or data advantages in healthcare, enterprise AI, and industrial technology.
Catalio is a New York-based investment firm focused on innovative healthcare, investing across the full lifecycle through private, public, and credit markets.
SOSV is a deep tech venture capital firm that makes first-check pre-seed investments and follow-on rounds in startups focused on human and planetary health, providing lab space and hands-on support at its US locations.
▶11 more co-investors
Mayfield Fund5AM VenturesJohnson & Johnson Innovation – JJDCRebel FundPJCMorpheus VenturesOmega FundsRoche Venture FundToba CapitalJDRF T1D FundAbbVie
Firms observed investing alongside Hatteras Venture Partners, from public investor directories. Shared companies are the overlap with Hatteras Venture Partners's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.